Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically …
M Fukuoka, YL Wu, S Thongprasert… - Journal of clinical …, 2011 - ascopubs.org
Purpose The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and
carboplatin/paclitaxel in previously untreated never-smokers and light ex-smokers with …
carboplatin/paclitaxel in previously untreated never-smokers and light ex-smokers with …
Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with …
M Fukuoka, Y Wu, S Thongprasert, C Yang… - Journal of Clinical …, 2009 - ascopubs.org
8006^ Background: IPASS demonstrated overall superiority of first-line G vs C/P for
progression-free survival (PFS) in never/light ex-smokers with stage IIIB/IV adenocarcinoma …
progression-free survival (PFS) in never/light ex-smokers with stage IIIB/IV adenocarcinoma …
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non–small-cell lung cancer: data from the randomized phase III INTEREST trial
JY Douillard, FA Shepherd, V Hirsh, T Mok… - Journal of clinical …, 2010 - ascopubs.org
Purpose In the phase III INTEREST trial, 1,466 pretreated patients with advanced non–small
cell lung cancer (NSCLC) were randomly assigned to receive gefitinib or docetaxel. As a …
cell lung cancer (NSCLC) were randomly assigned to receive gefitinib or docetaxel. As a …
Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer
Q Zhou, XC Zhang, ZH Chen, XL Yin… - Journal of clinical …, 2011 - ascopubs.org
Purpose Our aim was to determine whether abundance of epidermal growth factor receptor
(EGFR) mutations in tumors predicts benefit from treatment with EGFR–tyrosine kinase …
(EGFR) mutations in tumors predicts benefit from treatment with EGFR–tyrosine kinase …
Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with …
A Nakamura, A Inoue, S Morita, Y Hosomi, T Kato… - 2018 - ascopubs.org
9005 Background: Although EGFR-TKI alone has been a standard first-line treatment for pts
with advanced NSCLC with EGFR mutations, our phase II study (NEJ005) showed …
with advanced NSCLC with EGFR mutations, our phase II study (NEJ005) showed …
Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma
TS Mok, YL Wu, S Thongprasert… - … England Journal of …, 2009 - Mass Medical Soc
Background Previous, uncontrolled studies have suggested that first-line treatment with
gefitinib would be efficacious in selected patients with non–small-cell lung cancer. Methods …
gefitinib would be efficacious in selected patients with non–small-cell lung cancer. Methods …
A review of the benefit–risk profile of gefitinib in Asian patients with advanced non‐small‐cell lung cancer
K Park, K Goto - Current medical research and opinion, 2006 - Taylor & Francis
Background: Improvements in first-line therapy of advanced non-small-cell lung cancer
(NSCLC) have increased the need for effective second-line treatment options. In a Phase II …
(NSCLC) have increased the need for effective second-line treatment options. In a Phase II …
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non–small-cell lung cancer
FR Hirsch, M Varella-Garcia, PA Bunn Jr… - Journal of clinical …, 2006 - ascopubs.org
Purpose The phase III Iressa Survival Evaluation in Lung Cancer (ISEL) trial compared
gefitinib with placebo in 1,692 patients with refractory advanced non–small-cell lung cancer …
gefitinib with placebo in 1,692 patients with refractory advanced non–small-cell lung cancer …
Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non–small-cell lung cancer and poor performance …
Purpose To compare gefitinib with placebo in chemotherapy naïve patients with advanced
non–small-cell lung cancer (NSCLC) and poor performance status. Patients and Methods …
non–small-cell lung cancer (NSCLC) and poor performance status. Patients and Methods …
Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib …
Purpose To explore predictive factors for time to treatment failure (TTF) in chemotherapy-
naive non–small-cell lung cancer (NSCLC) patients receiving gefitinib treatment. Patients …
naive non–small-cell lung cancer (NSCLC) patients receiving gefitinib treatment. Patients …